Predicine is a global precision medicine company developing a portfolio of regulated liquid biopsy genomic products to help advance the science of precision medicine in cancer. Its patented GeneRADAR is a RNA + DNA-based liquid biopsy test for early cancer detection, disease monitoring, and minimal residual disease assessment. With its 600 gene-panel cancer diagnostics technology, patient enrollment program, vast data sets, and advanced analytics, Predicine has partnered with 30+ biopharmas to support their clinical trials in US, EU, Australia and China. Predicine operates in US and China